Technical Analysis for AMPH - Amphastar Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
AMPH closed down 0.46 percent on Wednesday, January 16, 2019, on 39 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Up||Up||Up|
|See historical AMPH trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 16||Shooting Star Candlestick||Bearish||0.00%|
|Jan 16||Overbought Stochastic||Strength||0.00%|
|Jan 15||180 Bullish Setup||Bullish Swing Setup||-0.46%|
|Jan 15||Upper Bollinger Band Walk||Strength||-0.46%|
|Jan 15||Inside Day||Range Contraction||-0.46%|
|Jan 15||Overbought Stochastic||Strength||-0.46%|
|Jan 14||Stochastic Sell Signal||Bearish||2.21%|
|Jan 14||Upper Bollinger Band Walk||Strength||2.21%|
|Jan 14||Overbought Stochastic||Strength||2.21%|
|Jan 14||Upper Bollinger Band Touch||Strength||2.21%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Amphastar Pharmaceuticals, Inc., a generic and specialty pharmaceutical company, engages in the discovery, development, manufacture, and marketing of generic and proprietary pharmaceuticals, delivery systems, and active pharmaceutical ingredients. The company focuses on injectable, inhalation, and other categories of pharmaceutical products. Its products include Enoxaparin Sodium Injection, which is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism and the inpatient/outpatient treatment of acute deep vein thrombosis; Amphadase, a protein enzyme that is prepared from a highly purified bovine testicular hyaluronidase; Cortrosyn for Injection, a diagnostic agent that is used in the screening of patients presumed to have adrenocortocal insufficiency; and prefilled disposable emergency syringes for crash cart use. The company's products also include Lidocaine HCl Jelly, a preservative-free topical local anesthetic agent that is provided in a prefilled syringe; Naloxone HCl Injection for the complete or partial reversal of narcotic depression and diagnosis of suspected acute opioid overdose; and Phytonadione Injection (Vitamin K1) for newborns. In addition, it markets its drug development pipeline and patented technologies. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California with manufacturing subsidiaries/facilities in South El Monte, California; and West Roxbury and Canton, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more AMPH news...
|52 Week High||22.74|
|52 Week Low||14.4|
|200-Day Moving Average||18.4842|
|50-Day Moving Average||20.5882|
|20-Day Moving Average||20.5535|
|10-Day Moving Average||21.215|
|Average True Range||0.7474|
|Chandelier Exit (Long, 3 ATRs )||20.0678|
|Chandelier Exit (Short, 3 ATRs )||21.1322|
|Upper Bollinger Band||22.3549|
|Lower Bollinger Band||18.7521|
|Percent B (%b)||0.84|
|MACD Signal Line||0.2105|
|Market Cap||1.01 Billion|
|Num Shares||46.2 Million|
|Price-to-Earnings (P/E) Ratio||272.25|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||22.67|
|Resistance 3 (R3)||22.74||22.53||22.52|
|Resistance 2 (R2)||22.53||22.30||22.49||22.47|
|Resistance 1 (R1)||22.15||22.16||22.05||22.08||22.42|
|Support 1 (S1)||21.56||21.71||21.46||21.49||21.14|
|Support 2 (S2)||21.35||21.57||21.31||21.09|
|Support 3 (S3)||20.97||21.35||21.04|
|Support 4 (S4)||20.90|